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Down-regulation of PTH-PTHrP receptor of heart in CRF: Role of
FCa2]1. The mRNA of PTH-PTHrP receptor in the kidney and liver of
CRF rats is down-regulated. It is not known whether this is a generalized
phenomenon and the signals that mediate such down-regulation are not
evident. Excess PTH in CRF induces a rise in basal levels of cytosolic
calcium ([Ca2]1), and the high [Ca2]1 is implicated in the genesis of cell
dysfunction in CRF. Therefore, it is reasonable to propose that the
PTH-induced rise in [Ca211 provides a negative feedback control system
for the down-regulation of the mRNA of the PTH-PTHrP in order to
protect the cells from the harmful effects of progressive rise in blood levels
of PTH in CRF. The heart contains the mRNA for this receptor and it is
a target organ for PTH action. We examined whether the message of the
PTH-PTHrP receptor is down-regulated in the heart of CRF animals and
evaluated the role of [Ca2]1 in this process. The expression of the mRNA
of the PTFI-PTHrP was significantly reduced in the heart of CRF rats as
compared to normal animals. Also, the CRF rats had elevated blood levels
of PTH and high [Ca2]1 of cardiac myocytes. The parathyroidectomy of
CRF rats prevented the rise in blood PTH levels and normalized [Ca2j1
of cardiac myocytes and returned the mRNA of their PTH-PTHrP
receptor towards normal levels. The treatment of CRF rats with verapamil
normalized [Ca2]1 of cardiac myocytes and returned the mRNA of their
PTH-PTHrP receptor towards normal levels, despite marked elevation of
blood levels of PTH. The data show that: (1) down-regulation of mRNA
of PTH-PTHrP receptor occurs in heart of CRF rats; (2) this is due to the
secondary hyperparathyroidism of CRF; and (3) one of the signals for this
phenomenon is the PTH-induced rise in basal levels of [Ca2]1. It is
proposed that the latter may adversely affect the gene expression and/or
increase the degradation of the mRNA of the PTH-PTFIrP receptor.
We [1] and others [2] have demonstrated that the mRNA of
the parathyroid hormone-parathyroid hormone related protein
(PTH-PTHrP) receptor in the kidney [1, 2] and liver [11 of animals
with CRF and secondary hyperparathyroidism is down-regulated.
This phenomenon appears to be an adaptive response to protect
the cells from continued action of the elevated blood levels of
PTH.
The signals through which chronic excess of PTH mediates its
effect on the mRNA of the PTH-PTHrP receptor are not known.
It is possible that the PTH-induced rise in cytosolic calcium
([Ca2J) of cells in CRF [31 constitutes one of such signals.
Indeed, limited data exist supporting such a proposition. It was
found that the prevention of the presumed rise in [Ca2]1 of the
kidney (a traditional organ for PTH action) by treatment of CRF
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animals with verapamil resulted in the return of the mRNA of the
PTH-PTHrP receptor toward normal levels despite elevated
blood levels of PTH [1]. Further data are needed to confirm such
a possibility. Also, if this finding represents a generalized phe-
nomenon, one must be able to document it in a non-traditional
organ for PTH action.
The heart is such an organ [4—71, and it contains the mRNA of
the PTH-PTHrP receptor [8, 9]. We therefore examined the
mRNA of this receptor in the heart of CRF rats, measured
[Ca2]1 in their cardiac myocytes, and evaluated the effect of
parathyroidectomy of these animals or their treatment with
verapamil on these parameters.
Methods
Sprague Dawley rats weighing 350 to 420 (366 5.0)g were
studied. They were pair fed and received normal chow diet (ICN
Nutritional Biochemical, Cleveland, OH, USA) throughout the
study and allowed to drink water ad libitum. The diet contained
1.4% calcium, 0.97% phosphorus, 24% fat and 4.4IUvitamin Dig.
Studies were performed in: (1) normal rats; (2) rats with CRF of
six weeks duration; (3) normocalcemic parathyroidectomized-
CRF (6 weeks) rats designated CRF-PTX; (4) rats with CRF of six
weeks duration treated with verapamil (0.1 j.gIg body wt) given
subcutaneously twice daily from day one of CRF (CRF-V); and
(5) normal rats treated with verapamil, as described above, for six
weeks (normal-V).
CRF was produced by right partial nephrectomy through a
flank incision and a week later, left nephrectomy was performed.
PTX was done with electrocautery, and the success of the
procedure was ascertained by a decrease in plasma levels of
calcium of at least 2 mgidl. The PTX rats were allowed to freely
drink water containing 5% calcium gluconate. This procedure is
adequate to normalize plasma levels of calcium in the PTX rats.
Seven days after PTX, the rats were subjected to 5/6 nephrectomy
as described above. Two days before sacrifice, the rats were
housed in metabolic cages for the collection of two consecutive 24
hours urine output for the calculation of creatinine clearance.
The animals were killed by decapitation; the hearts were removed
immediately, washed out of blood, and frozen in liquid nitrogen. The
total RNA was isolated from the heart by acid guanidinium thiocy-
anate-phenol-chloroform extraction as described by Chomczynski
and Sacchi [10] and later modified by them [11] using Trizol reagent.
The yields of total RNA (mg/g tissue) from the hearts of the various
groups of animal were not different (normal = 1.33 0.042, CRF =
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Table 1. Body weight, biochemical parameters and serum PTH levels in all groups of rats studied
N Bodyweight
Plasma mg/mi Serum PTH
pg/mi
.Creatinine clearance
pJ/minIlOO gCreatinine Calcium Phosphorus
Normal 12 378 9.2 0.30 0.01 9.7 0.3 7.0 0.5 16 1.3 532 18
CRF 10 360 13.7 1.08 0.12'-' 10.0 0.1 5.1 0.5° 40 44' 145 6b
CRF-PTX 8 309 106d 0.96 010b 10.1 0.2 5.9 0.3 9 1.7" 173 5"
CRF-V 10 350 8.1 1.03 0.13" 10.2 0.1 6.2 0.3 43 3.9' 168 11"
Nonnal-V 9 364 6.1 0.35 0.02 10.2 0.2 5.8 0.3 18 1.1 477 25
Data are presented as mean Sc.
ap < 0.05 vs. normal; b p < 0.01 vs. normal and normal-V; P < 0.01 vs. normal, CRF-PTX and normal-V; d P < 0.01 vs. all groups.
1.18 0.054, CRF-PTX = 1.18 0.064, CRF-V = 1.30 0.085 and
normal-V = 1.18 0.083).
The poly A RNA of the heart was prepared from the total
RNA according to the method of Ansubel et a! [12] and previously
reported by our laboratory [8]. The yield of poly A RNA (in %)
from the RNAwas 3.25 0.27 in normal rats, 2.10 0.31 in CRF
animals, 2.00 0.36 in CRF-PTX rats, 3.28 0.43 in CRF-V
animals, and 2.80 0.49 in normal-V rats. These values were not
statistically different.
R15B plasmid encoding the full length of the rat PTH-PTHrP
receptor was supplied by Dr. Geno V. Segre of the Massachusetts
General Hospital (Boston, MA, USA). This plasmid was cloned
into competent MC 1061/P3 cells (Invitrogen Corp, San Diego,
CA, USA), digested with the restriction enzyme Hind III, and
1200-bp fragment of the cDNA PTH-PTHrP receptor was recov-
ered by gel electrophoresis as described previously [8]. An aliquot
containing 30 ng of this fragment of the cDNA was labeled with 5
.tl of 32P dCTP (10 mCi/mi, Amersham, Arlington Heights, IL,
USA) using a Random Primed DNA Labelling Kit (Boehringer-
Manneheim, Indianapolis, IN, USA) and purified through G50
Sepharose (Sigma Chemical Co., St. Louis, MO, USA).
Aliquots of 4 g of poly A RNA of the heart were placed in
separate lanes of 1.2% agarose-formaldehyde gel and subjected to
electrophoresis in 1 X MOPS buffer (20 mci MOPS, 5 m sodium
acetate and 10 mci EDTA, pH 7.4) at 100 volts for three hours.
The separated poly A'- RNAs were transferred to Hybond N
nylon paper (Amersham) with 20 X SSC (1.5 M NaCI and 0.15 M
sodium citrate, pH 7.5) as described previously [1, 8]. The poly A
RNA was cross-linked to membrane in UV Strata Linker 1800
(Stratagene, La Jolla, CA, USA).
Prehybridization of the membrane was performed in 7% SDS,
1% polyethylene glycol, 2 X SSPE (0.9 M NaC1, 40 mci NaOH, 50
mM NaH2PO4, and 5 mci EDTA, pH 7.4) for two hours at 68°C
[131. Subsequently, the membrane was hybridized for 16 hours at
68°C with 10 ml of prehybridization solution plus 32P-labeled
cDNA probe of the PTH-PTHrP receptor (specific activity 106
cpm/ml). The membrane was washed twice (20 mm at 65°C) with
1% SDS, 50 mci NaC1, and 12 mM EDTA. The membrane was
then autoradiographed and analyzed by densitometric scanning
(LKB Ultroscan IX, Bromma, Sweden). Northern blot analysis
from the same poly A RNA was performed using eDNA probe
of 13-actin (Clontech Lab, Inc., Palo Alto, CA, USA). The amount
of mRNA of the PTH-PTHrP in the tissues from animals with
the various experimental conditions was normalized by calculating
the ratio between the mRNA of the receptor and the f3-actin in
the same tissue.
Measurement of [Ca2], was made in cardiac myocytes pre-
pared from the various groups of animals studied. Cardiac
myocytes were isolated from ventricles using a modification of the
methods of Dc Young et al [14] and Haworth et al [15]. The
details of the isolation technique used in our laboratory have been
reported [6]. [Ca2], in cardiac myocytes was measured by fura 2
AM using Perkin-Elmer fluorometer model [S 5B (Perkin-Elmer
Corp., Norwalk, CT, USA). The details of this methodology have
been reported from our laboratory [6]. The dissociation constant
for Ca2-fura 2 was assumed to be 225 n and calculation of
[Ca2I, was made using the Grynkiewicz equation [16].
The measurements of the concentration of plasma calcium were
made with Perkin-Elmer atomic absorption spectrophotometer,
model 503, and those of plasma creatinine and phosphorus and of
creatinine in urine with Technicon autoanalyzer (Technicon In-
strument, Inc., Tarrytown, NY, USA). Serum levels of PTH were
determined by INS-PTH immunoassay kit (Nichols Institute
Diagnosis, San Juan Capistrano, CA, USA). This assay recognizes
the aminoterminal fragment of PTH. The lowest detectable level
is 3 pg/mI; the interassay variation is 7.3%, and the intraassay
variation is 4%.
The results are presented as mean SE. Statistical analysis was
done with one way analysis of variance (ANOVA) and signifi-
cance was determined with the Bonferroni-Dunn test and by the
Fisher test.
Results
The body weight and the biochemical data in the five groups of
animals studied are given in Table 1. There were no significant
differences in the body weight among the normal CRF, CRF-V
and normal-V animals, while the CRF-PTX animals had lower
body weight than the other four groups. The 5/6 nephrectomy was
followed by a significant (P < 0.01) rise in the plasma concentra-
tion of creatinine and a decrease in creatinine clearance; there
were no significant differences in these parameters among the
three groups with CRF. The plasma concentrations of calcium
were not different among all groups studied while those of
phosphorus were lower in CRF rats than in the other four groups.
A low plasma phosphorus in CRF rats has been observed previ-
ously [17—19]. This may be due to the state of secondary hyper-
parathyroidism in the CRF rats which have moderate renal
failure. The serum concentration of PTH in CRF and CRF-V rats
was significantly higher (P < 0.01) than in normal, CRF-PTX, and
normal-V animals. These levels in CRF-PTX rats were signifi-
cantly lower than in normal and normal-V rats.
The mRNA of the PTH-PTHrP and of -actin in the heart of
normal, CRF and CRF-PTX and CRF-V and normal-V rats is
shown in Figures 1 and 2. The expression of mRNA of the
PTH-PTHrP in the heart of CRF rats is reduced in comparison to
that in the other groups of animals. Figure 3 provides the relative
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Fig. 1. Northern blot analysis of mRNA of PTH-PTHrP receptor and of /3-actin of the heart from normal rats (lane 1—4), CRF rats (lane 5—7) normal- V rats
(lane 8) and CRF-V (lane 9—Il).
PTH-PTHr P
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3-actin
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Fig. 2. Northern blot analysis of mRNA of PTH-PTHrP receptor and of 3-actin of the heart from CRE rats (lane 1—3), CRF-PTX rats (lane 4—6), normal
rats (lane 7 and 8), CRF-V (lane 9 and 10) and normal-V (11—13).
concentrations of the mRNA of the PTH-PTHrP receptor to that
of 13-actin in the heart. The value in the CRF rats (1.4 0.09%)
was significantly (P < 0.01) lower than that of normal rats (4.8
0.19%) and of CRF-PTX animals (3.7 0.13%). The treatment
of the CRF animals with verapamil was associated with an
increase in the mRNA concentration of the PTH-PTHrP receptor
with the relative value to that of /3-actin being 3.7 0.19%. In the
normal-V animals this value was 3.7 0.24%. Although the
values in the CRF-PTX, CRF-V and normal-V rats were modestly
lower than that in normal animals, the differences were not
statistically significant by the Bonferroni-Dunn test, but were
significant by the Fisher test.
Figure 4 depicts the mean values of the [Ca2]1 of cardiac
myocytes in the five groups of animals studied. The [Ca2] in
these cells obtained from CRF animals (101 3.2 nM) was
markedly and significantly (P < 0.01) elevated in comparison to
values in normal rats (56 1.6 nM). Both PTX of the CRF
animals or their treatment with verapamil resulted in normaliza-
tion of the levels of [Ca2]1, with the values being 57 2.1 nM and
58 2.4 n, respectively. The treatment of normal rats with
verapamil did not alter the levels of [Ca2]1 of the cardiac
myocytes (54 1.5 nM).
Discussion
The results of the present study demonstrate that the expres-
sion of the mRNA of the PTH-PTHrP receptor is significantly
reduced in the heart of rats with CRF and elevated blood levels of
PTH. Furthermore, the prevention of the secondary hyperpara-
thyroidism by parathyroidectomy prior to the induction of CRF
resulted in the return of the concentration of mRNA of the
receptor toward normal levels. Such a reduction in the expression
of mRNA of the PTH-PTHrP receptor would likely be associated
1 2 3 4 5 6 7 8 9 10 11
-2.4Kb
-2.3kb
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Fig. 3. The concentration of the mRNA of the PTH-PTHrP relative to that
of/3-actin in the five groups of animals studied. The values for the CRF rats
are significantly lower than those of the other four groups of animals.
There were no significant differences among the values of normal,
CRF-PTX, CRF-V and normal-V rats. Each column represents mean
value and brackets denote 1 SE. Symbols are: (El) Normal; (•) CRF; (0)
CRF-PTX; () CRF-Ver; () Normal-Ver.
with a decrease in the synthesis of the receptor, leading to a
decrease in the receptor concentration. This notion is plausible
but must remain tentative, since a suitable monoclonal antibody
for the PTH-PTHrP receptor that would permit the measurement
of the receptor protein is not as yet available. A decrease in the
concentration of PTH-PTHrP receptor in CRF would protect the
cells from the harmful effects of continued exposure to excess PTH.
Our findings on the mRNA of the PTH-PTHrP receptor in the
heart of CRF and CRF-PTX animals are similar to those reported
in kidney [1, 2] and liver of CRF animals [1]. Thus, it appears that
the down-regulation of the PTH-PTHrP receptor in CRF is a
generalized phenomenon and is due to the state of secondary
hyperparathyroidism. However, the mechanisms through which
excess PTH in blood mediates its action on the production of its
receptor are not clear.
PTH augments entry of calcium into many cells and the chronic
excess of PTH in CRF is associated with marked elevation in
[Ca2] of cells [3]. This elevation in [Ca2]1 appears to play a
major role in the pathogenesis of cell dysfunction in CRF [3].
Thus, it is important for the cells to down-regulate the PTH-
PTHrP receptor so that the increment in their [Ca2] does not
progress unabated as the blood levels of PTH continue to rise with
the progression of CRF.
Since the elevation in [Ca2] is produced by excess PTH and
since the rise in [Ca2} is the culprit in the genesis of cell
dysfunction in CRF [3], it is reasonable to propose that such an
elevation in [Ca2] should provide a negative feedback control of
the molecular machinery responsible for the synthesis of the
PTH-PTHrP receptor. If this proposition is indeed operative, one
would expect that an animal with CRF, elevated blood levels of
PTH and normal [Ca2] should not display a down-regulation of
the mRNA of the PTH-PTHrP receptor. Our finding that the
expression of the mRNA of the receptor in the heart of CRF-V
animals is near normal levels is consistent with this notion. This
Fig. 4. Basal levels of cytosolic calcium in cardiac myocytes of normal (El),
CRF (•), CRF-PTX (III), CRF-V () rats. Each column represents the
mean of 5 to 6 rats and brackets denote 1 SE. The values in CRF rats were
significantly higher than in the other four groups.
return of the message of the receptor toward normal level
occurred despite a significant elevation in blood level of PTH in
the CRF-V rats which are not different from those of CRF
animals. The only difference between these two groups of animals
is in the level of the [Ca2] of their cardiac myocytes, with the
values being normal in CRF-V rats and elevated in CRF animals.
Other observations support the notion that elevated level of
[Ca2] provides a cellular signal for the down-regulation of the
mRNA of the PTH-PTHrP receptor. First, treatment of CRF rats
with verapamil is also associated with an increase in the message
of the PTH-PTHrP receptor in the kidneys of these animals,
despite significant elevation in their blood levels of PTH [1].
Second, Yang and Tashjian [20] demonstrated that an increase in
[Ca2]1 of GH4C1 cells, induced by ionomycin, was associated with
a decrease in the mRNA of another hormone receptor, that is
thyroid releasing hormone (TRH) receptor. We would like to
emphasize that the rise in [Ca2]1 in CRF may not be the only
signal through which uremia and/or elevated blood levels of PTH
affects the concentration of the message of the PTH-PTHrP
receptor.
CRF is associated with an increase in the weight of the heart
[21, 22], and this phenomenon presumably reflects cardiac hyper-
trophy. It is, theoretically, possible that such hypertrophic process
is associated with a reduction in the concentration of the mRNA
of the PTH-PTHrP receptor. If PTX of CRF rats or their
treatment with a calcium channel blocker reverses cardiac hyper-
trophy, and if the latter is responsible for the decrease in mRNA
of the PTH-PTHrP receptor, one would expect an increase in the
mRNA of the receptor. Rambausek et al [21] found that PTX of
CRF rats or their treatment with the calcium channel blocker
diltiazem did not reduce the weight of their heart. These data,
therefore, are not consistent with a role of cardiac hypertrophy in
the reduction of the concentration of the mRNA of the PTH-
PTHrP receptor in CRF.
PT
H
-P
TH
r P
 re
ce
pt
or
 n
iR
N
A 
co
n
ce
n
tra
tio
n 
in
 h
ea
rt,
 %
 o
f /3
-a
ct
in
 m
R
N
A 
o
 
-
s 
N
) 
C.
) 
*
 
( 
0) 
4 
_
_
_
_
_
_
H
 
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
F'
 
a
- 
Cy
to
so
lic
 ca
lc
iu
m
, f
lM
 
a
 0 
0 
0 
*
 
1186 Smogorzewski et al: Heart PTH-PTHrP receptor and [Ca2 17, in CRF
The concentration of mRNA is determined by the balance
between its synthesis and degradation. Our study was not de-
signed to examine these processes. The data of Young and
Tashjian [20] provided evidence that a rise in [Ca2]1 adversely
affected the rate of gene transcription of TRH receptor of the
GH4C1 cells. Others have shown that CRF is associated with
increased degradation of albumin mRNA in liver [23]. Thus,
either one or both mechanisms may be at work to explain the
reduction in the concentration of the PTH-PTHrP receptor
mRNA in CRF.
It could be argued that down-regulation of mRNA of the
PTH-PTHrP receptor should be associated with reduction in
PTH-induced calcium influx into the cardiac myocytes and, there-
fore, their level of [Ca2] should not remain elevated. Such a
proposal may appear reasonable; however, this may not necessar-
ily be the case for at least two reasons. First, cardiac myocytes may
have a finite number of PTH receptors and under normal
circumstances with normal blood levels of PTH, only a small
fraction of these receptor is occupied. As blood levels of PTH
increase during the evolution of CRF more receptors become
occupied, and this process continues until all receptors are
occupied. At such a time, further elevation in blood levels of PTH
will not be followed by an additional rise in [Ca2]1. Such a
proposition is supported by our previous observations that [Ca2]1
of cardiac myocytes increased from 63 1.6 to 82 0.6 nM after
three weeks of CF and increased to 105 3.0 n by six weeks
of CRF as blood levels of PTH progressively increased [7]. Similar
observations were reported in pancreatic islets of CRF rats where
blood levels of PTH and [Ca2]1 of islets were measured weekly
during the evolution of CRF [24]. Therefore, it is possible that at
six weeks of CRF, the number of receptors occupied is equivalent
to the number of Ieceptors remaining after the down-regulation
process. Under such circumstances the [Ca2]1 of the cardiac
myocytes would remain elevated.
Second, it has been shown repeatedly and in many cells
including cardiac myocytes that the elevation in [Ca2]1 during
CRF is due not only to PTH-induced calcium entry into cells but
also to decreased calcium efflux as well [3, 7, 24]. The latter
derangement may maintain [Ca2]1 elevated even if calcium influx
is reduced after the down-regulation of PTH receptors.
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